Contribution: Industrial Research Assistance Program – Contributions to Firms
Tieos Pharmaceuticals Inc.
$44,327.00
PK and tolerability xenograft testing for lead oncology compound
EF 2018-19 · 2019-01-07
Résumé
Tieös Pharmaceuticals is a pre-clinical stage biotech company, with the goal of creating novel small molecule inhibitors which target the unique metabolic characteristics of cancer cells.
With the use of advanced AI-based computational biology and 3D in-silico models, we have developed lead polypharmocological compounds which will each target multiple metabolic pathways simultaneously; creating synergies and reducing toxicity. Through a proprietary weighting of cancer specific metabolic pathways, we have now synthesized our five lead compounds and are conducting proof-of-concept in-vitro testing.
At Tieös, we have designed compounds which target onco-specific enzymes simultaneously – our goal is to starve cancer cells of their energy.
Ministère
Programme
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (lien de confiance élevée)
Bénéficiaire
Emplacement
Moffat|Moffat, New Brunswick, Canada
Type de bénéficiaire
For-profit organization
Numéro d'entreprise
756525093
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Modifications
Chaque version de l'entente telle que publiée, de la plus ancienne à la plus récente, avec son total à cette version. Le montant ci-dessus est le plus récent.
| Modification | Date | Exercice financier | Total |
|---|---|---|---|
| 1 | 2019-01-07 | 2018-19 | $44,327.00 |
| 2 | 2019-01-07 | 2018-19 | $44,327.00 |
Tel que publié
Additional Information
This agreement has been amended 1 time(s). The total amendment value is 28,971 dollars.
Additional Information (French)
Cet accord a été modifié 1 fois ou la valeur totale des modifications est de 28 971 dollars.
Agreement End Date
2019-06-21
Agreement Number
919111
Agreement Start Date
2019-01-07
Agreement Title
PK and tolerability xenograft testing for lead oncology compound
Agreement Title (French)
Tests de xénogreffe pharmacocinétique et de tolérabilité pour le composé de plomb oncologique
Agreement Type
Contribution
Agreement Value
$44,327.00
Amendment Date
2019-04-02
Amendment Number
2
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
Tieös Pharmaceuticals is a pre-clinical stage biotech company, with the goal of creating novel small molecule inhibitors which target the unique metabolic characteristics of cancer cells.
With the use of advanced AI-based computational biology and 3D in-silico models, we have developed lead polypharmocological compounds which will each target multiple metabolic pathways simultaneously; creating synergies and reducing toxicity. Through a proprietary weighting of cancer specific metabolic pathways, we have now synthesized our five lead compounds and are conducting proof-of-concept in-vitro testing.
At Tieös, we have designed compounds which target onco-specific enzymes simultaneously – our goal is to starve cancer cells of their energy.
Description (French)
Tieös Pharmaceuticals est une entreprise de biotechnologie au stade préclinique, qui a pour objectif de créer de nouveaux inhibiteurs de petites molécules, qui ciblent les caractéristiques métaboliques uniques des cellules cancéreuses. En utilisant la biologie informatique avancée et les modèles 3D in-silico basés sur l'IA, nous avons développé des composés polypharmocologiques principaux, qui cibleront simultanément plusieurs voies métaboliques ; créant des synergies et réduisant la toxicité. Grâce à une pondération exclusive des voies métaboliques spécifiques du cancer, nous avons maintenant synthétisé nos cinq composés principaux et menons des tests de démonstration de faisabilité in vitro. Chez Tieös, nous avons conçu des composés, qui ciblent simultanément des enzymes onco-spécifiques. Notre objectif est de priver les cellules cancéreuses de leur énergie.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Moncton--Riverview--Dieppe
Federal Riding (French)
Moncton--Riverview--Dieppe
Federal Riding Number
13007
NAICS Code
3254
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
756525093
Recipient City
Moffat|Moffat
Recipient Country
CA
Recipient Legal Name
Tieos Pharmaceuticals Inc.
Recipient Postal Code
E1A 6N9
Recipient Province or Territory
NB
Recipient Type
F
Reference Number
172-2018-2019-Q4-919111
